Methods
n numerous population studies, uric acid (UA) has been shown to be a predictor of cardiovascular mortality, 1,2 and serum UA has been reported to increase in patients with chronic congestive heart failure (CHF). [3] [4] [5] Recent reports suggest that increased UA production through activation of xanthine oxidase (XO), a producer of UA from xanthine and hypoxanthine, is an important mechanism involved in the elevation of the serum UA level in CHF. 3 XO is also known as one of the main sources of free radicals [6] [7] [8] and may contribute to oxidative damage in the myocardium. 9 A chronic increase in myocardial oxidative stress is capable of causing subcellular abnormalities, and may lead to cardiomyopathic changes, depressed contractile function and failure. 10, 11 Thus, an elevated serum level of UA may relate to cardiac dysfunction and progression of heart failure through oxidative stress by increased XO activity in patients with CHF. However, to our knowledge, there are no reports about whether UA is produced in the failing human heart or about the relationship between a transcardiac increase in serum UA and left ventricular dysfunction in patients with CHF.
Anker et al in Germany reported that a high UA level predicted mortality and indicated the need for transplantation in patients with CHF; 12 however, they did not measure brain or B-type natriuretic peptide (BNP). High plasma BNP level is an important prognostic predictor in patients with CHF [13] [14] [15] [16] and acute coronary syndrome, 17, 18 suggesting that plasma BNP is a biochemical marker of hemodynamic abnormality. 19 From a clinical perspective, those studies raise then issue of whether serum UA and plasma BNP levels should be routinely measured in CHF patients. Altered renal excretion of UA caused by renal impairment or diuretics may contribute to hyperuricemia in CHF, so it is unclear whether serum UA is an independent prognostic predictor in relation to BNP and renal function.
In the present study, we measured serum UA level in the aortic root (AO) and the coronary sinus (CS) in 50 patients with CHF and 19 control subjects to evaluate whether UA is produced in the failing heart, and investigated the relationship between the transcardiac gradient of UA and left ventricular function. Second, to confirm the prognostic value of serum UA in Japanese patients with CHF, we measured it in 148 patients with CHF and monitored them prospectively for a long-term period.
was approved by the institutional Human Investigations Committee.
The subjects were 43 men and 7 women ranging in age from 16 to 81 years (mean 59.9±2.1); 32 had ischemic cardiomyopathy; 18 had dilated cardiomyopathy (DCM) diagnosed according to established criteria; 23 were classified as NYHA functional class II, 17 as class III and 10 as class IV. At entry to the study, 25 patients were treated with loop diuretics, 12 with spironolactone, 12 with digitalis, 41 with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers, 16 with -blockers, 12 with vasodilators. All drugs had been administered for more than 3 months prior to entry. We also selected 19 normal subjects (mean age, 59.8±2.9 years old) who were hospitalized for chest pain and whose hearts were defined as normal on cardiac catheterization and coronary angiography. None of the control subjects had histories of hypertension, diabetes mellitus, hypercholesterolemia or smoking.
Study 2 One hundred and forty-eight consecutive patients with mild to severe CHF (LVEF <45%, NYHA functional classes II-IV) who visited hospital between September 1998 and October 2002 were entered into study 2. Patients with inflammatory diseases, renal failure (eGFR <30 ml·min -1 ·(1.73 m 2 ) -1 ), malignancy or congenital malformations of the heart or vessels were excluded. Informed consent was given by all patients before participating in the study, and the protocol was approved by the institutional Human Investigations Committee.
The subjects were 113 men and 35 women ranging in age from 17 to 85 years (mean 61.0±1.1); 82 had ischemic cardiomyopathy; 66 had DCM diagnosed according to established criteria; 65 were classified as NYHA functional class II, 67 as class III and 16 as class IV. At entry to the study, 88 patients were treated with loop diuretics, 55 with spironolactone, 60 with digitalis, 113 with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers, 58 with -blockers, 37 with vasodilators and 19 with allopurinol. All drugs had been administered for more than 3 months prior to entry.
Study Protocols
Study 1 Blood samples were collected from the AO and the CS when the subjects underwent diagnostic cardiac catheterization. LVEF and left ventricular end-diastolic volume (LVEDV) were measured by left ventriculography.
Study 2 All patients rested in a supine position for at least 30 min before blood samples were collected from the peripheral vein. LVEF and LVEDV were then measured by echocardiography using the biplane disc summation method (Simpson's rule) in a blinded fashion. All patients were entered and followed prospectively, for a mean follow-up period of 1,304±46.3 days (range 15-2,175 days). All surviving patients were monitored prospectively for >2 years. The endpoint, which was judged independently by researchers, was cardiac death (worsening CHF, lethal myocardial infarction or sudden death).
Measurement of the Serum Level of UA and Plasma Levels of BNP and Norepinephrine (NE)
We measured the serum level of UA and plasma levels of BNP and NE in all blood samples. The serum UA level was measured by the uricase -peroxidase method and the plasma BNP level was measured with a specific immunoradiometric assay using a commercial kit (Shionogi, Osaka, Japan). 21 Plasma NE level was measured by high-performance liquid chromatography. 21 
Statistical Analysis
All results are expressed as the mean ± SEM. Univariate analyses were performed using Student's t-test. Comparisons between multiple groups were determined by one-way analysis of variance with Scheffe's test. Categorical data were compared against chi-square distribution. The prognostic value of the variables was tested in a Cox proportional hazards regression analysis. To determine whether the serum level of UA was an independent prognostic factor or only reflected the importance of other factors, 12 variables, as listed below, were entered into a Cox proportional hazard analysis. Kaplan-Meier analysis was performed on the cumulative survival rates in patients with chronic CHF stratified into 3 groups based on the median serum UA level and BNP level. A value of p<0.05 was considered significant.
Results

Transcardiac Production of UA in Patients With CHF
We measured the serum UA level in the AO and CS of 50 patients with CHF and 19 normal subjects. The 50 subjects were classified into 2 groups: mild CHF and severe CHF based on the NYHA class. The characteristics of the 2 groups are shown in Table 1 . Serum UA levels in the AO and CS increased with the severity of CHF. There was no difference in the serum UA level of the AO and CS in normal subjectsl; however, in the CHF patients the serum UA level was significantly higher in the CS than in the AO (Fig 1A,B) . The transcardiac gradient of UA (CS -AO) increased with the severity of CHF (Fig 1C) .
Relationship Between the Transcardiac Increase in (CS -AO) UA and Serum Level of UA
There was a significant correlation between the transcardiac increase in UA and the UA level in the AO (Fig 2) . To evaluate the influence of the transcardiac increase in UA on the serum level of UA, multivariate stepwise analysis was performed with 7 variables [age, gender, etiology, NYHA class, transcardiac increase in UA, use of loop diuretics or renal function]. The transcardiac increase in UA and loop diuretic administration were independent regulators of the serum level of UA (data not shown).
Correlation Between the transcardiac Gradient of UA and Left Ventricular Function in Patients With CHF
The transcardiac gradient of UA increased with the sever- 
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Severe CHF n=27 ity of CHF and inversely correlated with LVEF ( Fig 3A) and positively correlated with LVEDV index (LVEDVI) (Fig 3B) .
Patient Characteristics of 148 Patients With CHF (Table 2)
All of the 148 enrolled patients were successfully followed. During the follow-up period, 26 patients died of cardiac events: worsening CHF in 22 patients and sudden death in 4 patients. There were no differences between survivors and nonsurvivors according to age, gender, etiology, coronary risk factors, or eGFR. Loop diuretics administration, plasma levels of UA, BNP and NE were significantly higher, LVEF was significantly lower and LVEDVI was significantly larger in nonsurvivors than in survivors.
High Serum UA Level as an Independent Predictor of Mortality
By univariate analysis, LVEF, NYHA functional class, plasma levels of BNP and NE, and serum UA level were significant predictors of mortality. In 148 CHF patients, high plasma levels of UA (p<0.0001) and BNP (p<0.0001) were shown to be independent predictors of mortality by multivariate stepwise analysis (Table 3) .
Kaplan-Meier Survival for 148 Patients With CHF
Of the 40 patients 16 died (mortality rate =40%) (BNP ≥130 pg/ml and UA ≥6 mg/dl). Of the 46 patients only 1 died (BNP <130 pg/ml and UA <6 mg/dl) (Fig 4) . The hazard ratio for cardiac death was about 8 (p<0.0001, 95% confidence interval 3.0-19.9) for patients with BNP ≥130 pg/ml and UA ≥6 mg/dl compared to that of those with BNP <130 pg/ml or UA <6 mg/dl.
Discussion
This study demonstrated that (1) UA was released from the heart ofn CHF patients and the transcardiac gradient of UA correlated with the LVEDVI, LVEF and UA in the AO; and (2) a high serum level of UA was an important predictor of mortality, independent of the clinical and neurohumoral factors (GFR and BNP, respectively) previously associated with a poor prognosis in patients with mild to severe CHF. These results suggest that elevated serum UA is associated with myocardial dysfunction in patients with CHF. The findings of the present study on the prognostic role of UA in a Japanese population are consistent with those in the report by Anker et al, 12 and provide the additional information that not only high plasma levels of BNP but also UA are ndependent predictors of mortality. Therefore, the combination of UA and BNP may be useful for the management of CHF patients.
The activity of XO within the human myocardium is controversial. 22, 23 Coppola et al clearly showed that administration of allopurinol improves myocardial efficiency in patients with CHF due to cardiomyopathy and reported that the XO protein is increased in the failing heart compared with the normal heart. 24 In the present study, there was no difference in the serum UA level in the AO and the CS in normal subjects; however, in the CHF patients the serum UA level was significantly higher in the CS than in the AO (Fig 1A) . Therefore, by the direct sampling of UA from the CS and the AO the present study supports the previous observations. Although further studies of the prognostic role of UA before and after standard therapy for CHF are needed, a report 25 that UA decreases after allopurinol therapy in association with improved endothelial dysfunction, a potential independent prognostic predictor, 26, 27 supports our findings. However, further studies are needed to evaluate whether the transcardiac gradient of UA (CS -AO) is decreased by allopurinol administration.
A previous clinical study of CHF patients did not demonstrate any relationship of serum UA to LVEF or LVEDVI. 28 We included patients with relatively severe CHF patients compared with those in the former study and furthermore we measured the transcardiac gradient of UA, which increased with the severity of CHF. These differences in our study may support the possibility that XO is activated, especially in severe CHF, and contributes to cardiac dysfunction.
Beyond XO activity, recent experimental studies suggest that UA itself may play a role in cardiovascular pathology. The LIFE study demonstrated that lowering serum UA concentrations by losartan was associated with a beneficial effect on cardiovascular outcome. 29 In vitro and in vivo findings suggest that UA may contribute to endothelial dysfunction by inducing antiproliferative effects on endothelium and impairing nitric oxide production. 30 Therefore, sustained elevation of UA may contribute to the deterioration of CHF.
A recent clinical study report that inhibition of XO activity by allopurinol improves LV efficiency in patients with CHF. 24 Furthermore, a retrospective cohort study in CHF patients has demonstrated that long-term high-dose allopurinol administration was associated with reduced mortality compared with long-term low-dose administration. 31 Based on these reports, XO inhibition is potentially a novel therapeutic strategy for the treatment of human heart failure and it may be important to measure serum UA, as a marker of oxidative stress through XO activation, in patients with CHF.
Study Limitations
The transcardiac gradient of UA provided indirect evidence of XO activation in the heart, but the elevated serum level of UA may not be simply caused by increased cardiac XO activity, because the increase in the UA levels between the CS and AO was relatively small. Study 2 consisted of 150 subjects and there were 26 deaths, which is a relatively small number compared with large clinical trials. In the present study, treatments were not restricted and therefore Abbreviations see in Table 1 . the use of allopurinol was not an independent prognostic predictor ( Table 3 ), suggesting that patients with a high UA level with or without allopurinol treatment had a poor prognosis. Although further studies are needed to evaluate the mechanism of UA production, our findings suggest that a high plasma UA level, partly secreted from the failing heart, is a prognostic predictor independent of BNP in patients with CHF. Further studies are needed to evaluate (1) whether the combination of BNP and UA is useful for the management of patients with CHF and (2) the prognostic role of UA before and after standard therapy with allopurinol for CHF.
